Experimental drug trial aims to save children from Life-Threatening shock
NCT ID NCT07212686
Summary
This study is testing whether adding the drug Angiotensin II (brand name Giapreza) to standard treatments can help stabilize dangerously low blood pressure in critically ill children. Researchers will enroll 30 pediatric patients whose blood pressure remains dangerously low despite receiving fluids and other blood pressure medications. The study will monitor if the drug safely improves blood pressure and reduces the need for other strong medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASODILATORY SHOCK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cohen Children's Medical Center
Queens, New York, 11101, United States
-
Cohen Children's Medical Center of Northwell Health
New Hyde Park, New York, 11040, United States
Conditions
Explore the condition pages connected to this study.